In summary, the therapeutic use of mMSC-exos can reduce lung inflammation and the phenotype of BMDMs associated with MCMV-induced pneumonia by specifically inhibiting NF-κB/NLRP3 inflammasome signaling. This evidence concerns the gene NFKB1 and pneumonia.